Invenomic Capital Management Exits Haemonetics After Year of Underperformance
Key Takeaways
- Invenomic Capital Management has fully liquidated its $24.3 million stake in Haemonetics Corporation (HAE) following a period of significant market underperformance.
- The move signals a strategic shift for the fund as it reallocates capital toward more resilient healthcare and technology holdings.
Mentioned
Key Intelligence
Key Facts
- 1Invenomic Capital Management fully exited its 498,317-share position in Haemonetics Corporation (HAE).
- 2The liquidated stake was valued at approximately $24.29 million at the time of the filing.
- 3Haemonetics shares have declined 9% over the past year, significantly underperforming the S&P 500's 16% gain.
- 4The exit reduced Haemonetics from 1.2% of Invenomic's 13F AUM to 0%.
- 5Invenomic's largest remaining holdings include Viatris ($69.64M) and Global Payments ($61.73M).
- 6The SEC filing documenting the full exit was dated February 17, 2026.
| Company | |||
|---|---|---|---|
| Viatris | VTRS | $69.64 Million | 3.4% |
| Global Payments | GPN | $61.73 Million | 3.0% |
| Dentsply Sirona | XRAY | $58.66 Million | 2.8% |
| Akamai Technologies | AKAM | $58.59 Million | 2.8% |
| Haemonetics (Exited) | HAE | $0.00 | 0.0% |
Analysis
The recent decision by Invenomic Capital Management to fully exit its position in Haemonetics Corporation (HAE) marks a significant tactical shift for the investment firm, reflecting broader pressures within the medical device and blood management sectors. According to a February 17, 2026, SEC filing, Invenomic liquidated 498,317 shares, a position previously valued at approximately $24.29 million. This complete divestment reduced Haemonetics from a 1.2% weighting in the fund’s 13F assets under management (AUM) to zero, highlighting a loss of conviction in the company’s near-term recovery prospects.
Haemonetics has struggled to maintain pace with the broader market over the last twelve months. While the S&P 500 posted robust gains of roughly 16%, shares of Haemonetics declined by 9%, closing recently near the $58.58 mark. This divergence suggests that the company’s core business—automated plasma collection and blood component systems—is facing headwinds that the wider market has largely avoided. Analysts point to a combination of shifting hospital spending priorities and potential saturation in the plasma collection market as primary drivers for the stock's stagnation. For a fund like Invenomic, which manages over $2 billion in 13F assets, the opportunity cost of holding an underperforming asset in a bull market likely became too high to justify.
While the S&P 500 posted robust gains of roughly 16%, shares of Haemonetics declined by 9%, closing recently near the $58.58 mark.
The exit from Haemonetics contrasts sharply with Invenomic’s current top holdings, which show a preference for diversified healthcare and fintech stability. The fund’s largest position is now Viatris (VTRS), valued at $69.64 million, followed closely by Global Payments (GPN) and Dentsply Sirona (XRAY). This portfolio construction suggests that Invenomic is pivoting toward companies with stronger free cash flow profiles and more defensive market positions. By moving capital out of a specialized medical device player like Haemonetics and into broader healthcare entities like Viatris, the fund appears to be hedging against the volatility inherent in niche medical technology.
What to Watch
From a broader industry perspective, Haemonetics remains a critical player in the blood management ecosystem. Its integrated software solutions and automated devices are essential for plasma centers and hospitals. However, the company’s reliance on the plasma industry—a sector that has seen fluctuating donor volumes and regulatory scrutiny—introduces a level of risk that institutional investors are increasingly wary of. The liquidation by Invenomic may serve as a leading indicator for other institutional holders who are evaluating whether Haemonetics can regain its growth trajectory or if it will continue to lag behind its peers in the medical equipment space.
Looking ahead, investors should monitor Haemonetics' upcoming quarterly earnings for signs of margin improvement in its plasma business. The company’s ability to innovate in its hemostasis analyzer segment and software platforms will be crucial for attracting institutional capital back to the stock. For now, Invenomic’s exit underscores a 'wait-and-see' approach that is becoming more common among mid-sized hedge funds facing a bifurcated market where only the top performers are being rewarded with sustained capital inflows. The reallocation of these funds into sectors like gold (via Eldorado Gold) and cybersecurity (via Akamai) further suggests a defensive posture aimed at protecting gains in an uncertain macroeconomic environment.
How we covered this story
Every story in our finance coverage is assembled from multiple primary sources, cross-referenced for factual consistency, and scored along three independent dimensions: sentiment, operational impact, and source-cluster confidence. Single-source rumors and unverifiable claims do not pass our editorial gate. When a story shows "Verified by N sources" with N≥2, the development is independently corroborated; when N=1, we mark it explicitly so readers can weigh the signal accordingly.
Impact scoring uses a 1-10 scale weighted toward regulatory, financial, and operational consequence rather than coverage volume. A topic that runs in every outlet but moves no real decisions ranks lower than a niche regulatory filing that reshapes how operators in the finance space have to behave. Read our full methodology for the scoring rubric, our glossary for term definitions, and our trends index for the longitudinal view across the beat.
| Signal on this page | What it tells you |
|---|---|
| Verified by N sources | Independent corroboration count. N≥2 is our confidence floor; N=1 is marked explicitly. |
| Impact score (1-10) | Regulatory + financial + operational weight. 8+ signals an experienced-operator action item. |
| Sentiment | Five-tier classification trained on labeled finance-specific corpora. |
| Timeline | Where applicable, the related-events sequence that contextualizes today's development. |